Tirzepatide before and after: what to expect from clinical data

Tirzepatide produced the largest weight loss ever recorded in a non-surgical obesity trial. In the SURMOUNT-1 study, participants on the highest dose lost an average of 22.5% of their body weight over 72 weeks [1]. On a 250-pound person, that’s 56 pounds.

Unlike semaglutide, which targets only the GLP-1 receptor, tirzepatide is a dual GIP/GLP-1 receptor agonist. That dual mechanism appears to produce meaningfully better weight loss results at every dose tested. Here’s what the trial data actually shows, broken down by timeline and dose.

Results snapshot

Metric	5 mg	10 mg	15 mg
Mean weight loss at 72 weeks	16.0%	21.4%	22.5%
Achieved ≥5% loss	89.4%	96.3%	96.3%
Achieved ≥10% loss	73.4%	86.1%	90.1%
Achieved ≥20% loss	35.0%	55.5%	62.9%
Achieved ≥25% loss	16.5%	35.0%	39.7%
Placebo weight loss	3.1%	3.1%	3.1%

Data from SURMOUNT-1, n=2,539 [1]

Those numbers are worth sitting with. Nearly 40% of participants on the 15 mg dose lost a quarter of their body weight. That’s territory previously reserved for bariatric surgery.

What to expect: a week-by-week timeline

Weeks 1 through 4: starting at 2.5 mg

Everyone begins at 2.5 mg regardless of their target dose. This four-week introductory period lets your GI tract adjust. Weight loss during this phase is minimal, typically 1% to 2% of body weight. But appetite suppression kicks in quickly. Most participants report eating less without trying within the first two weeks [1].

GI side effects start here too. Nausea is the most common, but it’s usually mild. Eating smaller portions and avoiding greasy foods helps.

Weeks 4 through 12: dose escalation

The dose increases by 2.5 mg every four weeks. By week 8, you’re at 5.0 mg. By week 12, you’re at 7.5 mg (if targeting 10 mg or 15 mg). Weight loss accelerates during this period. In a post hoc analysis of SURMOUNT-1, participants who lost at least 5% of body weight by week 12 went on to achieve substantially greater total weight loss by week 72 [3].

This phase is where you’ll notice your eating patterns changing. Food still tastes good, but the compulsive pull toward overeating fades. Many people describe it as feeling “neutral” about food for the first time.

Weeks 12 through 24: reaching target dose and visible changes

If your target is 15 mg, you’ll reach it around week 20. By the six-month mark, most participants had lost 10% to 15% of body weight depending on dose [1]. On someone who started at 250 pounds, that’s 25 to 37 pounds.

This is typically when other people start to notice. Changes in face shape, waist measurement, and how clothes fit become obvious. If you’re interested in how tirzepatide stacks up against other options, our semaglutide vs tirzepatide comparison covers the head-to-head trial data.

Weeks 24 through 48: sustained loss

Weight continues to drop, though the rate slows. This isn’t a stall. It’s the same deceleration pattern seen with all weight loss medications. The body adapts to its new lower weight, and the rate of loss naturally decreases.

At the 10 mg and 15 mg doses, participants were still losing weight at week 48. The gap between the 5 mg group and the higher-dose groups widened during this period [1].

Weeks 48 through 72: maximum results

By week 72, the final numbers came in: 16.0% (5 mg), 21.4% (10 mg), and 22.5% (15 mg) average weight loss. Placebo participants lost 3.1% [1]. The difference between the 10 mg and 15 mg groups was relatively small (about 1 percentage point), suggesting that 10 mg captures most of the benefit for many people.

Clinical trial results by the numbers

SURMOUNT-1: the landmark obesity trial

SURMOUNT-1 enrolled 2,539 adults with BMI ≥30 (or ≥27 with a weight-related condition) without type 2 diabetes. It randomized participants to tirzepatide 5 mg, 10 mg, 15 mg, or placebo, all with lifestyle intervention, for 72 weeks [1].

The results were published in the New England Journal of Medicine in 2022. At every dose, tirzepatide outperformed placebo by wide margins. The 15 mg dose produced weight loss nearly matching gastric sleeve outcomes in some studies.

SURMOUNT-2: participants with type 2 diabetes

Like all GLP-1 medications, tirzepatide produces less weight loss in people with type 2 diabetes. SURMOUNT-2 found up to 15% weight loss in participants with T2D, which is still more than semaglutide achieved in its equivalent trial (STEP 2: 9.6%) [4].

For people with T2D looking for both weight loss and blood sugar control, tirzepatide has a meaningful advantage. It improved HbA1c levels alongside weight reduction.

SURMOUNT-3: with intensive lifestyle intervention

When tirzepatide was added after a 12-week intensive lifestyle intervention (including a low-calorie diet), results were even better. Participants who had already lost weight through diet changes then added tirzepatide on top. Total weight loss from the initial baseline was substantial [5].

SURMOUNT-4: weight maintenance

SURMOUNT-4 addressed what happens after you’ve lost weight. Participants who responded to tirzepatide during an open-label lead-in were randomized to continue or switch to placebo. Those who continued maintained their weight loss. Those who switched to placebo regained weight [6]. Same pattern as what semaglutide data shows: you need to stay on the medication to keep the results.

Head-to-head vs semaglutide

A direct comparison trial published in the New England Journal of Medicine found tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide at 72 weeks (P<0.001) [7]. That’s a 6.5 percentage point advantage for tirzepatide, which translates to roughly 15 more pounds lost for someone starting at 230 pounds.

Side effects during treatment

Tirzepatide’s side effect profile is similar to other GLP-1 medications. GI events are most common and usually occur during dose escalation [8]:

Side effect	Tirzepatide (pooled)	Placebo
Nausea	24% to 33%	9.5%
Diarrhea	18% to 23%	8.9%
Vomiting	9% to 13%	2.8%
Constipation	11% to 17%	4.8%

Compared to semaglutide, tirzepatide’s nausea rates were somewhat lower in pooled analyses (24-33% vs. 44% for semaglutide), though direct comparisons across trials are imperfect [8]. Discontinuation due to adverse events ranged from 3% to 7% across the SURMOUNT program, which is low for a weight loss medication [8].

Most GI side effects were mild to moderate and transient. They peaked during dose escalation weeks and improved once participants stabilized at their target dose.

Factors that affect results

Dose matters. The jump from 5 mg to 10 mg produced 5.4 percentage points more weight loss. The jump from 10 mg to 15 mg added only 1.1 more. If side effects limit your dose, 10 mg still produces strong results.

Type 2 diabetes. People with T2D consistently lose about 5-7 percentage points less than those without. This applies to tirzepatide just as it does to semaglutide and other GLP-1s.

Early response predicts outcomes. SURMOUNT-1 post hoc data showed that participants who lost ≥5% by week 12 achieved significantly greater total loss by week 72 [3]. If you’re not seeing movement in the first 12 weeks, talk to your provider about dose adjustment.

Body composition changes. Tirzepatide reduces both fat mass and lean mass, though fat loss accounts for the majority. Resistance training and adequate protein intake help preserve muscle.

Adherence to the dose schedule. Weekly injections need to happen consistently. Missed doses slow progress and can trigger side effects when you restart.

Tips for best results

Prioritize protein. During rapid weight loss, your body draws on both fat and muscle for energy. Getting 1.2 to 1.6 grams of protein per kilogram of body weight per day helps protect lean mass. This is especially important given the magnitude of weight loss tirzepatide produces.

Add resistance training. Two to three sessions per week of resistance exercise preserves muscle mass and supports metabolic rate. The SURMOUNT trials included lifestyle counseling, and participants who were more active tended to do better.

Follow the escalation schedule. Your provider will increase your dose every four weeks. Don’t skip ahead or slow down without medical guidance. The schedule was designed to balance efficacy against GI tolerability.

Stay hydrated. GI side effects like nausea and constipation are easier to manage with adequate fluid intake. Aim for at least 64 ounces of water daily, more if you’re active.

If you’re ready to explore whether tirzepatide is right for you, our guide to buying tirzepatide online covers what to look for in a telehealth provider.

FAQ

How much weight will I lose on tirzepatide?▼

In the SURMOUNT-1 trial, average weight loss ranged from 16.0% (5 mg) to 22.5% (15 mg) over 72 weeks [1]. About 63% of participants on the highest dose lost 20% or more of their body weight. Individual results vary.

How quickly does tirzepatide work?▼

Appetite suppression starts within the first two weeks for most people. Measurable weight loss begins within the first month. By week 12, most participants had lost enough weight to predict their longer-term trajectory [3].

Is tirzepatide better than semaglutide for weight loss?▼

In a head-to-head trial, tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide at 72 weeks [7]. Tirzepatide outperformed semaglutide at a statistically significant level. See our full semaglutide vs tirzepatide comparison.

What are the brand names for tirzepatide?▼

Mounjaro is tirzepatide approved for type 2 diabetes. Zepbound is tirzepatide approved for weight management. Compounded tirzepatide is available through compounding pharmacies at lower cost. Learn more about tirzepatide online prescriptions.

Will I regain weight if I stop tirzepatide?▼

SURMOUNT-4 showed that participants who stopped tirzepatide regained weight, while those who continued maintained their loss [6]. Current evidence supports ongoing treatment for sustained results.

Who qualifies for tirzepatide?▼

Generally, adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition (high blood pressure, high cholesterol, type 2 diabetes, or sleep apnea). An online weight loss doctor can evaluate your eligibility.

How much does tirzepatide cost?▼

Brand-name Zepbound costs $1,000+ per month without insurance. Compounded tirzepatide through online clinics typically ranges from $300 to $500 per month. See our peptide therapy pricing guide for current numbers.

Can I take tirzepatide if I have type 2 diabetes?▼

Yes. Tirzepatide (as Mounjaro) is FDA-approved for T2D and produces both weight loss and HbA1c improvement. Weight loss results are lower than in non-diabetic populations, averaging up to 15% in SURMOUNT-2 [4].

Ready to see what tirzepatide can do for you? Start your free evaluation at PURE →

References

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038

2. Heerspink HJL, Sattar N, Pavo I, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes and chronic kidney disease: the SURPASS-4 trial. Lancet Diabetes Endocrinol. 2022.

3. Eli Lilly. Weight reduction over time in tirzepatide-treated participants by early weight loss response: post hoc analysis in SURMOUNT-1. 2025.

4. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626.

5. Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909-2918. doi:10.1038/s41591-023-02597-w

6. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48.

7. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025. doi:10.1056/NEJMoa2416394

8. Rubino DM, Calanna S, Davies M, et al. Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight in the SURMOUNT-1 to -4 trials. Diabetes Obes Metab. 2025. doi:10.1111/dom.16176